染色体1q+的发展 针对高风险儿科的特殊治疗 后垂体瘤
Andrea M Griesinger1,2, Annaliese J Calzadilla1,2, Enrique Grimaldo1,2
1Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, Colorado.
概括
新的组合疗法对高风险的儿科内膜瘤 (PFA) 是有前途的. 这种方法结合了5-fluorouracil (5FU),ATRA和辐射,针对PFA瘤中的染色体1q增长 (1q+),为改善生存提供了希望.
科学领域:
- 儿科瘤学 儿科瘤学
- 癌症遗传学 癌症遗传学
- 辐射瘤学 辐射瘤学
背景情况:
- 最高风险的后腔组A尾瘤 (PFA) 缺乏有效的治疗方法.
- 染色体1q增长 (1q+) 在PFA中很常见,特别是在复发时,并且与糟糕的结果有关.
- 开发针对1q+PFA的向疗法至关重要.
研究的目的:
- 为了评估1q+PFA的联合辐射和化疗的临床前疗效.
- 研究1q染色体在治疗反应中的作用.
主要方法:
- 使用了1q+PFA的体外和体外模型.
- 经过测试的组合疗法,包括5-甲 (5FU),ATRA和辐射.
- 评估了细胞增殖和细胞亡标志物.
主要成果:
- 在1q+PFA细胞系中,5-甲 (5FU) 增强了放射治疗,通过UCK2在1q.染色体上通过增加p53活性来增加1q+PFA细胞系的放射治疗.
- 结合5FU,ATRA和辐射在体外显著降低了增殖和增加了亡.
- 在体内研究表明,与组合疗法治疗的小鼠的生存率有所提高.
结论:
- 这项研究确定了第一个染色体1q+特定治疗1q+PFA的第一个染色体1q+.
- 在儿科I期试验中确定的5FU和ATRA的安全性和剂量支持在高风险PFA的II期试验中加快临床应用.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...